Department of Internal Medicine, Creighton University Medical Center, Omaha, NE, USA;
Cancer Manag Res. 2009 Nov 12;1:155-65. doi: 10.2147/cmr.s5299.
There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for treatment of these patients. Bendamustine is a uniquely structured alkylating agent that lacks cross-resistance with other alkylators. This agent has a high degree of activity against a variety of tumor cell lines. Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma. Moreover, studies have validated its activity in patients with indolent NHL who are resistant to purine analogs and rituximab. The cytotoxic activity of bendamustine has been shown to be synergistic with rituximab in hematological malignancies. The incidence of alopecia is significantly less than with other alkylating agents. Myelosuppression is the major toxicity associated with bendamustine.
对于复发/难治性惰性非霍奇金淋巴瘤（NHL）的治疗，目前尚未达成共识。盐酸苯达莫司汀（苯达莫司汀）最近已被批准用于治疗这些患者。苯达莫司汀是一种结构独特的烷化剂，与其他烷化剂无交叉耐药性。该药物对多种肿瘤细胞系具有高度活性。临床上，苯达莫司汀对惰性 NHL、慢性淋巴细胞白血病、多发性骨髓瘤和套细胞淋巴瘤均具有活性。此外，研究已经证实其在对嘌呤类似物和利妥昔单抗耐药的惰性 NHL 患者中的活性。苯达莫司汀的细胞毒性活性与血液系统恶性肿瘤中的利妥昔单抗具有协同作用。脱发的发生率明显低于其他烷化剂。骨髓抑制是与苯达莫司汀相关的主要毒性。
